Loading...
Loading...
Bacterin International Holdings, Inc.
, a leader in the
development of revolutionary bone graft material and coatings for medical
applications, is pleased to announce it has obtained 510(k) approval to market
OsteoSelect® DBM Putty for use in spinal fusion procedures. OsteoSelect® is a
moldable bone graft substitute designed to withstand irrigation while
exhibiting osteoinductive properties for improved bone regeneration. The
cohesive nature of the product provides an advantage over other commercially
available DBM putties which can readily wash away after placement in wet,
surgical environments.
As part of the regulatory approval process, Bacterin provided funding to
Hospital for Special Surgery in New York to perform a study evaluating the
efficacy of OsteoSelect® in a rabbit posterolateral lumbar spine fusion model.
Biomechanical, radiographic, and histological analysis indicated that
OsteoSelect® showed equivalence to a control of autologous iliac crest bone
graft which is widely considered to be the gold standard for spinal fusion.
"We are proud to obtain another indication for use that will provide Bacterin
with additional marketing opportunities for the OsteoSelect® DBM Putty product
line," said Gregory Juda, PhD, Bacterin's Chief Scientific Officer. Dr. Juda
continued to say, "In the 3 plus years of OsteoSelect® being on the market, we
have seen considerable adoption by the orthopedic community across a variety
of surgical specialties. Our post market surveillance supports the efficacy of
OsteoSelect® and the results of the preclinical work validate the clinical
findings."
OsteoSelect® DBM Putty is a malleable bone grafting material comprised of
demineralized bone matrix allograft combined with a polymer carrier material.
The product was engineered using feedback from key opinion leaders in several
orthopedic specialties, with a focus on providing solutions to the
shortcomings inherent to other commercially available DBM products. The
osteoinductive potential of every lot of OsteoSelect® is confirmed after
sterilization in an animal model thus providing surgeons with a bone grafting
solution that is both safe and biologically active.
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in